

CRITICAL REVIEW FORM: THERAPY

Citation: Baharoglu MI, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous intracerebral hemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 2016;387:2605-13.

How serious is the risk of bias?	
Did intervention and control groups start with the same prognosis?	
Were patients randomized?	
Was randomization concealed?	
Were patients in the study groups similar at baseline with respect to prognostic factors?	
Was prognostic balance maintained as the study progressed?	
To what extent was the study blinded?	
Were groups prognostically balanced at the study's conclusion?	
Was follow-up complete?	
Were patients analyzed in the groups to which they were randomized?	
Was the trial stopped early?	
What are the results?	
How large was the treatment effect?	
How precise was the treatment effect?	
How can I apply the results to my patient care?	
Were the study patients similar to my patient?	

Were all patient-important outcomes considered?	
Are the likely benefits worth the potential harms and costs?	

Adapted from Duke and McMaster Evidence-based Practice Workshops and Users' Guide to the Medical Literature 3rd Ed.